Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;28(6):680-690.
doi: 10.22038/ijbms.2025.85335.18442.

Psoriasis: Immunological and genetic blueprints driving pathogenesis and potential for personalized therapies

Affiliations
Review

Psoriasis: Immunological and genetic blueprints driving pathogenesis and potential for personalized therapies

Mohamed J Saadh et al. Iran J Basic Med Sci. 2025.

Abstract

Psoriasis is a long-lasting inflammatory skin condition that impacts millions globally. The occurrence of this disorder differs significantly across various areas, resulting from a complex interplay of genetic and environmental influences. In psoriasis, the pathogenesis represents a complex interaction of innate and adaptive immunity that plays a significant role in the disease manifestation process. Many genetic factors predispose to psoriasis, which is considered a polygenic disease. Several genes concerning pathways like NF-κB and PI3K/Akt that modulate the amplification of inflammatory response and keratinocyte dysregulation have been elaborated in the light of their differential expression, susceptibility loci, and polymorphisms. Such genetic insights could open a whole new avenue for precision medicine in which biomarkers and gene-targeting therapies are promising options for personalized treatment. This review emphasizes the need for complex investigations into psoriasis, from molecular mechanisms to clinical manifestations, to bridge the gap between basic research and therapeutic development by furthering the understanding of psoriasis and paving the way for innovative treatments addressing skin lesions and systemic effects.

Keywords: Genetic predisposition; Immunopathogenesis; Inflammation; Personalized medicine; Psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Role of LL37 in the progression of psoriasis
Figure 2
Figure 2
Phosphorylation of Akt by PDK1 and PDK2, its activation, and the downstream modulation of keratinocyte growth, survival, and proliferation through FOXO and mTOR
Figure 3
Figure 3
Formation of the AIM2 inflammasome complex (the red circle), resulting in the release of IL-1β from psoriatic keratinocytes

Similar articles

References

    1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ. 2020;369:1590. - PMC - PubMed
    1. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1475–1493. - PMC - PubMed
    1. Kimmel GW, Lebwohl M. Psoriasis: Overview and Diagnosis. Evidence-Based Psoriasis. 2018;7:1–16.
    1. Zeng C, Tsoi LC, Gudjonsson JE. Dysregulated epigenetic modifications in psoriasis. Exp Dermatol. 2021;30:1156–1166. - PubMed
    1. Mateu-Arrom L, Puig L. Genetic and epigenetic mechanisms of psoriasis. Genes (Basel) 2023;14:1619–1636. - PMC - PubMed

LinkOut - more resources